As a member of our risk score model, tryptophan 2,3-dioxygenase 2 (TDO2) catalyzes the commitment step of the KYN metabolic process, which subsequently activates the AhR and contributes to an immunosuppressive TME, and supports the cancer immune escape [40,41]. The gene discussed is TDO2; the disease is cancer.